<DOC>
	<DOCNO>NCT00003304</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient recurrent oligodendroglial tumor follow combination chemotherapy .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Recurrent Oligodendroglial Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate duration response oligodendroglial tumor temozolomide treatment patient progressive disease procarbazine/lomustine/vincristine ( PCV ) chemotherapy . II . Determine feasibility toxicity temozolomide chemotherapy follow PVC chemotherapy patient . OUTLINE : This open label , multicenter trial . Temozolomide administer orally day 1-5 4-week course ; treatment continue maximum 12 course . Patients follow every 2 month first 6 month every 3 month thereafter . PROJECTED ACCRUAL : A total 16-29 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven oligodendroglioma oligoastrocytoma ( least 25 % oligodendroglial element ) Recurrent progressive disease follow radiotherapy procarbazine/lomustine/vincristine chemotherapy ( nitrosoureasbased chemotherapy ) Contrast enhancing , measurable disease ( least one lesion measure least 1 cm ) CT MRI require Within 2 week prior study treatment Within 3 day follow concurrent surgery recurrence Steroid dose stable decrease least 2 week prior scan No extracranial disease PATIENT CHARACTERISTICS : Age : 1869 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN AST/ALT great 2 time ULN Renal : Creatinine great 1.25 time ULN Creatinine clearance least 60 mL/min Other : Not pregnant lactate Effective contraception require fertile woman No disease interfere followup PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No one prior chemotherapy regimen At least 4 week since prior chemotherapy Prior nitrosourea require At least 6 week since nitrosourea Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics More 3 month since radiotherapy Surgery : Not specify Other : No concurrent treatment investigational agent antitumor agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>adult oligodendroglioma</keyword>
</DOC>